PDCD1 and pancreatic ductal adenocarcinoma: For instance, the combination of programmed cell death 1 (PD-1) inhibitors with chemotherapy drugs has shown both efficacy and safety in treating metastatic pancreatic ductal adenocarcinoma with liver metastases, offering new insights for LIHC treatment (13).